蛋白降解
- 分子胶 & PROTAC
- ADC
- Trastuzumab deruxtecan
- Sacituzumab govitecan
- Trastuzumab Emtansine
- Patritumab deruxtecan
- Vorsetuzumab mafodotin
- Anetumab-MMAE
- Clivatuzumab-MMAE
- Indusatumab vedotin
- Lifastuzumab vedotin
- Anetumab ravtansine
- Polatuzumab vedotin-piiq
- Zilovertamab vedotin
- Farletuzumab-MMAE
- Iladatuzumab vedotin
- Pinatuzumab vedotin
- Sirtratumab vedotin
- Codrituzumab-MMAE
- Cetuximab-MMAE
- Tusamitamab ravtansine
- Serclutamab talirine
- Cantuzumab mertansine
- Cantuzumab ravtansine
- Ozuriftamab vedotin
- Lorvotuzumab mertansine
- Sofituzumab vedotin
- Laprituximab emtansine
- Enapotamab vedotin
- Praluzatamab ravtansine
- Depatuxizumab mafodotin
- 多泛素化修饰
-
- 泛素活化酶 E1
- Pevonedistat
- TAK-243
- PYR-41
- ML792
- COH000
- 蛋白酶体降解
- 线粒体自噬调控 [1]
-
- USP30
- MF-094
-
- PINK1
- Gemcitabine
- 1400W 2HCl
- 溶酶体途径
- 内吞调控
- Dansylcadaverine
- Pitstop 2
- Methyl-β-cyclodextrin
- Chlorpromazine
- 相关化合物库
- Protease Inhibitor Library
- Protein-protein Interaction Inhibitor Library
- Ubiquitination Compound Library
- Autophagy Compound Library
